CHAIR
:
SPEAKER
(S):
Hugh Cole, Vice President of Business Development , Shire Human Genetic Therapies, Inc
Linda Friedman, JD, Senior Vice President & General Counsel , Astellas Pharma US
Mary Ellen Meyers, Director, Bus Dev , Chiesi Farmaceutici SpA
William Watson, PhD, Senior Partnering Director , Teva Pharmaceutical Industries, Ltd
David Weitz, JD, Vice President, US Intellectual Property and General Counsel , Takeda San Diego, Inc
Description
"Many European and Japanese pharmaceutical companies want to expand their development and commercialization activities in the United States. Different approaches to achieve those goals range from out-licensing to a U.S. partner to establishing their own full-fledged U.S. business unit and everything in between. We will examine the pros and cons of these various approaches and the experiences that our panelists' companies have had in building (and buying) a U.S. presence."
Objective1: Explore the different trends and precedents for European and Japanese pharmaceutical companies in approaching the U.S. market.
Objective2: Identify pros and cons of the different approaches to expanding into the U.S. market from Europe and Japan.
Objective3: Share war stories ranging from the good (what worked best) to the bad (what worked less well) to the ugly (what lessons you can learn from a fiasco).